|Elevation Pharmaceuticals, 8/12||$430M|
Sunovion Pharmaceuticals Inc. engages in discovering, developing, and commercializing therapeutic products for patients suffering from central nervous system disorders, respiratory disorders, and other illnesses. Its products include LUNESTA medicine that helps people sleep better; XOPENEX levalbuterol HCl inhalation solution; and BROVANA aformoterol tartrate inhalation solution. The companyâ€™s products also comprise OMNARIS ciclesonide nasal spray; ALVESCO ciclesonide HFA inhalation aerosol; and LATUDA, an oral antipsychotic tablet for the treatment of schizophrenia. It offers products for the treatment of depression, epilepsy, neuropathic pain, and insomnia, as well as respiratory conditions, such as asthma, allergic rhinitis, and chronic obstructive pulmonary diseases. Sunovion Pharmaceuticals Inc. was formerly known as Sepracor, Inc. and changed its name in October 2010. The company was founded in 1984 and is headquartered in Marlborough, Massachusetts. As of October 20, 2009, Sunovion Pharmaceuticals Inc. operates as a subsidiary of Dainippon Sumitomo Pharma America Holdings, Inc.